Additionally, Chi3l1 can markedly blunt hepatic insulin signaling as measured by reduced pAKT, pGSK-3β, and pERK levels in NAFLD, suggesting that Chi3l1 may play a role in the development of hepatic insulin resistance associated with inflammation and lipid deposition [79]. Here, CHI3L1 is linked to metabolic dysfunction-associated steatotic liver disease.